Background: Tracking medication adherence through an ingestible event monitoring (IEM) sensor could benefit seriously mentally ill patients (SMI). Psychiatric providers may be reluctant t...
Background: A new digital medicine technology combining an ingestible event monitoring (IEM) sensor with an oral antipsychotic to track ingestion and adherence may be beneficial. However,...
BACKGROUND: Ustekinumab was approved by the FDA in September 2016 for the treatment of patients with moderate-to-severe Crohn’s Disease (CD). Little is published about either the health a...